肝癌血液生物标志物的未来
本文综述了血液生物标志物在肝癌(肝细胞癌和胆道癌)全程管理中的应用前景,涵盖风险分层、监测与早期检测、治疗决策和疗效监测。尽管游离DNA检测可操作变异已在特定情境进入临床,但大多数候选标志物仍需通过嵌入临床试验的前瞻性研究进行严格验证。
要点
- 血液生物标志物有望用于肝癌风险分层、监测、早期检测及疗效监测。
- 游离DNA检测可操作变异已在特定情境进入临床实践。
- 多数候选标志物仍缺乏前瞻性临床验证,需嵌入临床试验评估。
核心结论
- 血液生物标志物在肝癌全程管理中具有广阔前景,但多数仍需前瞻性临床验证。
研究设计与样本
- 综述,总结血液生物标志物在肝细胞癌和胆道癌全程管理中的现状。
主要发现
- 游离DNA检测可操作变异已在特定情境进入临床实践。
- 大多数候选液体生物标志物仍需通过嵌入临床试验的转化研究和前瞻性队列研究进行严格评估。
临床怎么用
- 游离DNA检测可操作变异可在特定情境下用于临床决策。
- 其他候选血液标志物应优先纳入前瞻性临床试验或队列研究验证。
局限性
- 尽管研究增多,前瞻性临床验证仍然有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liquid biomarkers hold substantial promise in liver cancer, with potential applications in risk stratification, surveillance and early detection, therapeutic decision-making, and treatment-response monitoring. In parallel with oncologic advances, liquid biopsy has gained increasing attention. However, despite expanded research efforts, prospective clinical validation remains limited. While cell-free DNA-based detection of actionable alterations has entered clinical practice in select contexts, most candidate liquid biomarkers still require rigorous evaluation through translational research embedded in clinical trials and prospective cohort studies. In this review, we summarise the current landscape of blood-based biomarkers across the cancer care continuum for individuals at risk, or diagnosed with hepatocellular carcinoma and biliary tract cancers, and discuss the key challenges and opportunities that lie ahead.
引用
- Singal AG, Saborowski A, Parikh ND, et al. The future of blood-based biomarkers in liver cancer. J Hepatol. 2026. PMID: 42601275. doi:10.1016/j.jhep.2026.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。